Treating in the dark: unanswered questions on costs and benefits of late line therapy for metastatic breast cancer.
Anders
Carey K
CK
Department of Hematology-Oncology, University of North Carolina/Lineberger Cancer Center, Chapel Hill, North Carolina, USA. carey anders@med.unc.edu
Peppercorn
Jeffrey
J
D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000556:secondary; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D018803:Models, Economic; D013997:Time Factors
D000970:Antineoplastic Agents